Zilretta (triamcinolone acetonide extended-release inject susp)

Covered only as a single 32 mg intra‑articular Zilretta injection for management of knee osteoarthritis; non‑knee or non‑intra‑articular uses, repeat doses, and prior Zilretta recipients are excluded. Approval requires radiologic confirmation of knee OA, documentation of inadequate response to a prior intra‑articular corticosteroid injection, proof the patient has not previously received Zilretta, and supporting clinical records.

"Approval duration: 1 dose."

Sign up to see full coverage criteria, indications, and limitations.